Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Albitar

Showing results (1-10 of 5) with videos related to

Pageof 1
Sort By:
International Journal of Laboratory Hematology|January 23, 2016
Positive selection and high sensitivity test for MYD88 mutations using locked nucleic acidA Albitar, W Ma, I DeDios, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|May 21, 2020
An international survey to evaluate systemic bevacizumab for chronic bleeding in hereditary haemorrhagic telangiectasiaHanny Al-Samkari, Hasan A Albitar, Scott E Olitsky, et al.
Orphanet Journal of Rare Diseases|November 16, 2019
Systemic bevacizumab for high-output cardiac failure in hereditary hemorrhagic telangiectasia: an international survey of HHT centersHanny Al-Samkari, Hasan A Albitar, Scott E Olitsky, et al.
Leukemia|August 24, 2017
Prevalence of somatic mutations in patients with aplastic anemia using peripheral blood cfDNA as compared with BMA Albitar, D Townsley, W Ma, et al.
Haematologica|July 18, 2020
An international, multicenter study of intravenous bevacizumab for bleeding in hereditary hemorrhagic telangiectasia: the InHIBIT-Bleed studyHanny Al-Samkari, Raj S Kasthuri, Joseph G Parambil, et al.
Pageof 1

Showing results (1-10 of 5) with videos related to

Sort By:
Pageof 1
International Journal of Laboratory Hematology|January 23, 2016
Positive selection and high sensitivity test for MYD88 mutations using locked nucleic acidA Albitar, W Ma, I DeDios, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|May 21, 2020
An international survey to evaluate systemic bevacizumab for chronic bleeding in hereditary haemorrhagic telangiectasiaHanny Al-Samkari, Hasan A Albitar, Scott E Olitsky, et al.
Orphanet Journal of Rare Diseases|November 16, 2019
Systemic bevacizumab for high-output cardiac failure in hereditary hemorrhagic telangiectasia: an international survey of HHT centersHanny Al-Samkari, Hasan A Albitar, Scott E Olitsky, et al.
Leukemia|August 24, 2017
Prevalence of somatic mutations in patients with aplastic anemia using peripheral blood cfDNA as compared with BMA Albitar, D Townsley, W Ma, et al.
Haematologica|July 18, 2020
An international, multicenter study of intravenous bevacizumab for bleeding in hereditary hemorrhagic telangiectasia: the InHIBIT-Bleed studyHanny Al-Samkari, Raj S Kasthuri, Joseph G Parambil, et al.
Pageof 1